The linker histone H1.0 generates epigenetic and functional intratumor heterogeneity

INTRODUCTION Cancer arises from clonal expansion of a single cell. Yet, most human cancers are characterized by extensive intratumor heterogeneity and comprise various subpopulations of cells with distinct phenotypes and biological properties. Intratumor heterogeneity poses major challenges in understanding cancers, managing patients, and designing effective treatment strategies. Functional heterogeneity within individual tumors is partly due to the presence of genetically distinct subclonal cell populations. Furthermore, interactions between cancer cells and the tumor microenvironment can alter the phenotype of cancer cells via nongenetic mechanisms. The combination of cell-intrinsic and cell-extrinsic changes occurring during tumor growth generates functionally distinct subsets of cells that differentially contribute to tumor maintenance. RATIONALE In many cancers, phenotypic and functional heterogeneity can be mapped to distinct differentiation states, suggesting that cellular hierarchies established during tumor growth may affect the long-term proliferative potential of cancer cells. To shed light on the mechanisms responsible for the generation of these hierarchies, we searched for epigenetic mechanisms that determine which cancer cells can preserve unlimited proliferative potential, and thus the ability to drive long-term tumor growth, and which cells lose this ability through a differentiation process. RESULTS We found that, in several cancer types, individual tumors exhibit high heterogeneity of the major chromatin protein linker histone H1.0, showing strongly reduced H1.0 levels in cells characterized by long-term self-renewal ability and tumorigenic potential and higher levels in nontumorigenic cells. Combined analysis of pan-cancer patient data sets and experimental alteration of the H1F0 locus in tumor cells revealed that heterogeneous H1.0 expression patterns are partly due to differential methylation of an enhancer region that dynamically modulates H1.0 expression within tumors. Using a controlled system to model functional intratumor heterogeneity, we showed that maintenance of cell tumorigenic potential required silencing of H1.0 to avoid loss of unlimited proliferative capacity through differentiation. Mechanistically, absence of H1.0 led to destabilization of nucleosome-DNA interactions in AT-rich genomic regions and coordinated derepression of large sets of neighboring genes, resulting in activation of transcriptional programs that support cancer cell self-renewal. Gene expression changes induced by H1.0 loss were reversible, and epigenetic states restricting cell proliferative potential were reestablished upon H1.0 reexpression. In multiple cancer types, in agreement with the observed inhibition of cancer cell self-renewal by H1.0, patients expressing overall strongly reduced levels of H1.0 showed a significantly worse outcome than patients expressing higher H1.0 levels. CONCLUSION Intratumor heterogeneity has emerged as a general feature of cancer, but the molecular features underlying functionally diverse cellular phenotypes have been elusive. Our results uncover epigenetic determinants of tumor-maintaining cells and identify an integral component of chromatin as an important regulator of cell differentiation states within tumors. We propose that only cells insensitive to extracellular differentiation cues, capable of permanently silencing H1.0, can act as self-renewing tumor-maintaining cells and that such a mechanism supports maintenance of several types of cancer. Our results suggest that intervention aimed at restoring high levels of H1.0 in all cancer cells may enhance the differentiation process that naturally occurs during tumor growth and may be beneficial for therapeutic purposes. Epigenetic heterogeneity within tumors. In many cancer types, self-renewing and differentiated epigenetic states coexist in individual tumors. (Left) Image of a breast cancer section showing heterogeneous levels of the linker histone H1.0 (red). (Right) Schematic depiction of the chromatin status of cancer cells in which H1.0 is down-regulated (blue) or expressed at high levels (red). Tumors comprise functionally diverse subpopulations of cells with distinct proliferative potential. Here, we show that dynamic epigenetic states defined by the linker histone H1.0 determine which cells within a tumor can sustain the long-term cancer growth. Numerous cancer types exhibit high inter- and intratumor heterogeneity of H1.0, with H1.0 levels correlating with tumor differentiation status, patient survival, and, at the single-cell level, cancer stem cell markers. Silencing of H1.0 promotes maintenance of self-renewing cells by inducing derepression of megabase-sized gene domains harboring downstream effectors of oncogenic pathways. Self-renewing epigenetic states are not stable, and reexpression of H1.0 in subsets of tumor cells establishes transcriptional programs that restrict cancer cells’ long-term proliferative potential and drive their differentiation. Our results uncover epigenetic determinants of tumor-maintaining cells.

[1]  N. Takakura,et al.  Tumor microenvironment for cancer stem cells. , 2016, Advanced drug delivery reviews.

[2]  Vanja Tadić,et al.  Repurposing the CRISPR-Cas9 system for targeted DNA methylation , 2016, Nucleic acids research.

[3]  Runsheng Chen,et al.  The long noncoding RNA lncTCF7 promotes self-renewal of human liver cancer stem cells through activation of Wnt signaling. , 2015, Cell stem cell.

[4]  S. Baylin,et al.  Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. , 2014, Molecular cell.

[5]  Shawn M. Gillespie,et al.  Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma , 2014, Science.

[6]  Stylianos E. Antonarakis,et al.  Domains of genome-wide gene expression dysregulation in Down’s syndrome , 2014, Nature.

[7]  Simon Kasif,et al.  Reconstructing and Reprogramming the Tumor-Propagating Potential of Glioblastoma Stem-like Cells , 2014, Cell.

[8]  T. Meehan,et al.  An atlas of active enhancers across human cell types and tissues , 2014, Nature.

[9]  A. Krešo,et al.  Evolution of the cancer stem cell model. , 2014, Cell stem cell.

[10]  G. Massonnet,et al.  Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists , 2013, Nature.

[11]  N. McGranahan,et al.  The causes and consequences of genetic heterogeneity in cancer evolution , 2013, Nature.

[12]  Thomas A. Down,et al.  Chromatin Accessibility Data Sets Show Bias Due to Sequence Specificity of the DNase I Enzyme , 2013, PloS one.

[13]  Bruno Di Stefano,et al.  Polycomb complexes in stem cells and embryonic development , 2013, Development.

[14]  E. Nestler,et al.  diffReps: Detecting Differential Chromatin Modification Sites from ChIP-seq Data with Biological Replicates , 2013, PloS one.

[15]  David A. Orlando,et al.  Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes , 2013, Cell.

[16]  I. Amit,et al.  High-throughput chromatin immunoprecipitation for genome-wide mapping of in vivo protein-DNA interactions and epigenomic states , 2013, Nature Protocols.

[17]  Bradley E. Bernstein,et al.  Genome-wide Chromatin State Transitions Associated with Developmental and Environmental Cues , 2013, Cell.

[18]  K. Polyak,et al.  Intra-tumour heterogeneity: a looking glass for cancer? , 2012, Nature Reviews Cancer.

[19]  Jesse R. Dixon,et al.  Topological Domains in Mammalian Genomes Identified by Analysis of Chromatin Interactions , 2012, Nature.

[20]  Y. Benjamini,et al.  Summarizing and correcting the GC content bias in high-throughput sequencing , 2012, Nucleic acids research.

[21]  P. Giresi,et al.  Using formaldehyde-assisted isolation of regulatory elements (FAIRE) to isolate active regulatory DNA , 2012, Nature Protocols.

[22]  C. Caldas,et al.  Cancer stem cell markers in breast cancer: pathological, clinical and prognostic significance , 2011, Breast Cancer Research.

[23]  Pradeep S Rajendran,et al.  Single-cell dissection of transcriptional heterogeneity in human colon tumors , 2011, Nature Biotechnology.

[24]  M. J. Barrero,et al.  Histone H1 Variants Are Differentially Expressed and Incorporated into Chromatin during Differentiation and Reprogramming to Pluripotency* , 2011, The Journal of Biological Chemistry.

[25]  T. Misteli,et al.  In vitro generation of human cells with cancer stem cell properties , 2011, Nature Cell Biology.

[26]  Steven M. Johnson,et al.  Determinants of nucleosome organization in primary human cells , 2011, Nature.

[27]  Ryan A. Flynn,et al.  A unique chromatin signature uncovers early developmental enhancers in humans , 2011, Nature.

[28]  A. Angers-Loustau,et al.  Timing of the cell cycle exit of differentiating hippocampal neural stem cells. , 2010, International journal of stem cells.

[29]  P. Pelicci,et al.  Biological and Molecular Heterogeneity of Breast Cancers Correlates with Their Cancer Stem Cell Content , 2010, Cell.

[30]  Timothy R. Hughes,et al.  G+C content dominates intrinsic nucleosome occupancy , 2009, BMC Bioinformatics.

[31]  H. Fine,et al.  SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. , 2009, Cell stem cell.

[32]  Rafael A. Irizarry,et al.  Genome-wide methylation analysis of human colon cancer reveals similar hypo- and hypermethylation at conserved tissue-specific CpG island shores , 2008, Nature Genetics.

[33]  R. Schneider,et al.  The histone H1 family: specific members, specific functions? , 2008, Biological chemistry.

[34]  R. Beroukhim,et al.  Molecular definition of breast tumor heterogeneity. , 2007, Cancer cell.

[35]  J. Lieb,et al.  Cell Cycle–Specified Fluctuation of Nucleosome Occupancy at Gene Promoters , 2006, PLoS genetics.

[36]  Giorgio Bernardi,et al.  An isochore map of human chromosomes. , 2006, Genome research.

[37]  J. Itskovitz‐Eldor,et al.  Assessment of the ultrastructural and proliferative properties of human embryonic stem cell-derived cardiomyocytes. , 2003, American journal of physiology. Heart and circulatory physiology.

[38]  A. Vinogradov Bendable genes of warm-blooded vertebrates. , 2001, Molecular biology and evolution.

[39]  J. Widom,et al.  Poly(dA-dT) Promoter Elements Increase the Equilibrium Accessibility of Nucleosomal DNA Target Sites , 2001, Molecular and Cellular Biology.

[40]  R. McLendon,et al.  A genetically tractable model of human glioma formation. , 2001, Cancer research.

[41]  Robert A. Weinberg,et al.  Creation of human tumour cells with defined genetic elements , 1999, Nature.

[42]  D. Doenecke,et al.  Organization and expression of the developmentally regulated H1(o) histone gene in vertebrates. , 1996, The International journal of developmental biology.

[43]  D. Doenecke,et al.  Early increase in histone H1(0) mRNA during differentiation of F9 cells to parietal endoderm. , 1988, The EMBO journal.

[44]  M. Bustin,et al.  Monoclonal antibodies against distinct determinants of histone H5 bind to chromatin. , 1984, Biochemistry.

[45]  R A Laskey,et al.  High sequence specificity of micrococcal nuclease. , 1981, Nucleic acids research.

[46]  P. Nowell The clonal evolution of tumor cell populations. , 1976, Science.

[47]  K. Illmensee,et al.  Totipotency and normal differentiation of single teratocarcinoma cells cloned by injection into blastocysts. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[48]  W. Hahn,et al.  Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. , 2001, Genes & development.

[49]  G. Heppner Tumor heterogeneity. , 1984, Cancer research.

[50]  Nikolaus Rajewsky,et al.  Modeling the Initiation and Progression of Human Acute Leukemia in Mice , 2022 .